Reference is made to the press release dated August 14 2025, regarding the financing facility with Long State Investments Limited (“Long State”).
Softox Solutions AS ("SoftOx") today announces that the board of directors has resolved to request the issuance of up to 60 million shares under the financing facility, which will be invested into the Company through a private placement by Long State.
This initiate a 10-day pricing period stipulated under the financing agreement. The subscription price for the share placement will mainly be a function of the VWAP of the Company's shares during this pricing period, but not below the minimum subscription price of 0,10 set by SoftOx. Upon completion of this process, the relevant number of the Company's shares will be issued to Long State at the relevant price. The subscription price and volume will be calculated and announced upon the expiry of the pricing period.
For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com
About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.